Portola Pharma (PTLA) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 8, 2017 4:35 PM EDTSOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today reported financial results and provided a corporate update for the quarter ended March 31, 2017.
During the first quarter of 2017 we continued to focus on regulatory activities for betrixaban and AndexXa. Our goal is to gain approval for both products this year in the United States and in 2018 in the European Union, said Bill Lis, chief executive officer of Portola. Both are highly anticipated by the medical community because they are potentially life-saving medicines in indications where currently there are no approved therapies.
... More